The FDA on Monday said that instead of investigating a Chinese manufacturer of an ingredient for Baxter International's blood thinner heparin, it inspected another facility with a similar name. The agency said the incident was an isolated case and that it will visit the Chinese factory this week. Baxter's plant in Cherry Hill, N.J., and another supplier's facility in Waunakee, Wis., are also undergoing inspection.

Full Story:
ABC News

Related Summaries